Antihypertensive and organ-protective action of a 36-week monotherapy with telmisartan in hypertensive patients

Cite item

Full Text


Aim. To study hypotensive effectiveness and organ-protective properties of telmisartan in patients with essential hypertension (EH).
Material and methods. The trial enrolled 33 patients with EH of stage II, blood pressure (BP) elevation of the first and second degree, with ultrasound-diagnosed left ventricular (LV) hypertrophy and/ or increased thickness of intima-media complex (IMC) of the muscular-elastic vessels. The patients received 40-80 mg/day telmisartan monotherapy for 36 weeks. Hypotensive efficacy of the drug was assessed at 24-hr BP monitoring, a protective effect - at echocardiography and ultrasound duplex scanning of the vessels.
Results. A 36-week telmisartan monotherapy significantly improved all the analysed parameters of 24-hr BP monitoring. LV myocardial mass reduced by 12.7%, index of this mass - by 12.9%. Overall thickness of intima-media of the muscular-elastic vessels (common carotid and femoral arteries) lowered by 11.9%.
Conclusion. Long-term telmisartan monotherapy improves parameters of 24-hr BP monitoring, protects the heart and the vessels against remodeling, promotes reduction of LV hypertrophy and intima-media thickness of muscular-elastic arteries.


  1. Chobanian A., Bakris G., Black H. et al. The seventh report of joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. J. A. M. A. 2003; 289: 2560-2572.
  2. Национальные рекомендации по профилактике, диагностике и лечению артериальной гипертонии, 2-й пересмотр. - Комитет экспертов ВНОК. - М., 2004.
  3. Weinberg M. S., Weinberg A. J., Zappe D. H. Effectively targeting the RAAS in cardiovascular and renal disease: rational for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. J. RAAS 2000; 1(3): 217-233.
  4. Schmieder A. et al. Reversal of LVH in essential hypertension: meta-analysis of randomized double-blind studies. J. A. M. A. 1996; 275: 1507-1513.
  5. Alam M. G., Barri Y. M. Systolic blood pressure is the main etiology for poorly controlled hypertension. Am. J. Hypertens. 2003; 16: 140-143.
  6. Verdecchia P., Clement D., Fagard R. et al. Target-organ damage, morbidity and mortality. Blood Pressure Monitor. 1999; 4: 303-317.
  7. Kario K. Early morning risk management in hypertension. London: Science press; 2004. 3-11.
  8. Neutel J. M., Smith D. H. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv. Ther. 1998; 15: 206-217.
  9. Dahlof B., Devereux R. B., Kjeldsen S. E. et al. for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study: a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
  10. Viberti G., Wheeldon N. M. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with tape 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
  11. Burke G. L., Evans G. W., Riley W. A., Sharrett A. R. for ARIC Study Group. Arterial wall thickness in associated with prevalent cardiovascular disease in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995; 26: 386-391.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies